Tumores Mamários
Estudo randomizado | Escore baseado em painel genético para avaliar o benefício da quimioterapia para o câncer de mama com nódulo positivo.
2 Dez, 2021 | 11:17h21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer – New England Journal of Medicine (link para o resumo – $ para o texto completo)
Comentário no Twitter
Among postmenopausal women with HR–positive, HER2-negative breast cancer, 1-3 positive lymph nodes, and a 21-gene recurrence score of 25 or lower, 5-year invasive disease–free survival was similar whether they received endocrine or chemoendocrine therapy. https://t.co/aZLXBvSHHl pic.twitter.com/EBVnMkGHx4
— NEJM (@NEJM) December 2, 2021
Avanços na radioterapia para câncer de mama: implicações para as práticas atuais e futuras.
30 Nov, 2021 | 12:03h
Comentário no Twitter
Advances in #BreastCancer radiotherapy allow shorter regimens and reduced toxicities. This #JCOOP Clinical review summarizes the latest evidence in #radonc for #bcsm @CshahMD ➡️ https://t.co/JxvU5FSQlv pic.twitter.com/GOcwAFJzRm
— Journal of Clinical Oncology (@JCO_ASCO) October 31, 2021
Estudo randomizado | Novo programa de exercícios reduziu a disfunção de membro superior 1 ano depois de cirurgia para câncer de mama sem reconstrução.
19 Nov, 2021 | 12:21hComentários:
Exercise reduces upper limb disability after breast cancer surgery – BMJ / News Medical
Exercise Helps Ease Arm, Shoulder Pain After Breast Cancer Surgery- HealthDay
Structured Exercise Improves Upper Limb Function After Breast Ca Surgery – Physician’s Weekly
Comentário no Twitter
Women who exercise shortly after having non-reconstructive breast cancer surgery appear to regain better shoulder and arm mobility and experience less pain than those who receive standard care, finds this study @jxbruce https://t.co/BhIKb8RRjV
— The BMJ (@bmj_latest) November 11, 2021
Revisão | Panorama do tratamento do câncer de mama triplo-negativo.
16 Nov, 2021 | 12:25hTreatment landscape of triple-negative breast cancer — expanded options, evolving needs – Nature Reviews Clinical Oncology (gratuito por tempo limitado)
Comentário no Twitter
A Review in @NatRevClinOncol describes the current and upcoming therapeutic landscape of triple-negative breast cancer. https://t.co/bcFTef01t1 pic.twitter.com/zFPyeeCnD5
— Nature Portfolio (@NaturePortfolio) November 15, 2021
Revisão clínica sobre o tratamento de câncer de mama metastático positivo para receptor hormonal.
11 Nov, 2021 | 15:58hAmplo estudo observacional sugere a associação entre antipsicóticos que aumentam a prolactina e risco aumentado de câncer de mama (OR = 1,56 para mais de 5 anos de exposição); por outro lado, antipsicóticos poupadores de prolactina (clozapina, quetiapina ou aripiprazol) não estão associados a tal risco.
10 Nov, 2021 | 12:36hAntipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland – The Lancet Psychiatry (link para o resumo – $ para o texto completo)
Comentário no Twitter
Nested case-control study: ≥5 years exposure to prolactin-sparing APDs was not associated with an increased risk of breast cancer vs.<1 year exposure (aOR=1.19; 0.90–1.58). The opposite was observed with APDs that increase prolactin (aOR=1.56; 1.27–1.92) https://t.co/LwCVyTH051
— PfOL (@psychopharmacol) September 12, 2021
Linfadenopatia regional pós-vacinação contra COVID-19: revisão da literatura e considerações para a abordagem de pacientes em tratamento de câncer de mama.
9 Nov, 2021 | 12:22hConteúdos relacionados:
2 Case Series and Guidance | Lymphadenopathy in COVID-19 Vaccine Recipients
Análise do FDA | Sobrevida geral de pacientes com câncer de mama positivo para receptor hormonal, HER2 negativo, metastático ou avançado tratado com inibidor de quinase 4/6 dependente de ciclina com fulvestrante.
9 Nov, 2021 | 12:02hOverall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis – The Lancet Oncology (link para o resumo – $ para o texto completo)
Comentário no Twitter
A pooled analysis of phase III trials of fulvestrant plus either CDK4/6 inh or placebo in pts with HR+/HER2- advanced-stage #breastcancer shows an mOS benefit of 7.1 months (over a mFU of 43.7 months) favouring CDK4/6i (HR 0.77, 95% CI 0.68–0.88): https://t.co/ZMa0J8gS8Q #bcsm
— NatureRevClinOncol (@NatRevClinOncol) October 21, 2021
Estudo randomizado | Irradiação eletiva de linfonodo mamário interno não aumenta a sobrevida livre de doença ou a sobrevida geral na maioria das mulheres com câncer de mama com linfonodo acometido.
27 Out, 2021 | 12:31hEffect of Elective Internal Mammary Node Irradiation on Disease-Free Survival in Women With Node-Positive Breast Cancer: A Randomized Phase 3 Clinical Trial – JAMA Oncology (gratuito por tempo limitado)
Comentário: No Survival Benefit for Internal Mammary Node Irradiation in Breast Cancer — Women with medially or centrally located tumors may be candidates, however, says researcher – MedPage Today (necessário cadastro gratuito)
Comentário no Twitter
Phase III randomized study evaluated the role of internal mammary node irradiation (IMNI) in node-positive #breastcancer. IMNI did not improve the DFS in unselected patients, but did improve DFS in patients with medially or centrally located tumors https://t.co/tw4ZrHn5wn pic.twitter.com/34ye3TR9MA
— JAMA Oncology (@JAMAOnc) October 25, 2021
Diretriz de prática clínica da ESMO para diagnóstico, estadiamento e tratamento de pacientes com câncer de mama metastático.
21 Out, 2021 | 11:12hComunicado de imprensa: metastatic breast cancer: new ESMO guideline with evidence-based recommendations – European Society of Medical Oncology